Diabetic ketoacidosis precipitated by COVID-19 in patient with newly diagnosed diabetes mellitus

E. Xhardo, P. Kapisyzi, A. Rada
University Hospital "Sefqet Ndroqi", Tirana, Albania

Abstract. Background. Coronavirus disease 2019 (COVID-19) is a viral infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Diabetes mellitus (DM) have been reported frequently in patients with the new corona virus disease — 2019, COVID-19. It has been associated with progressive course and worse outcome. There is scarce data on diabetic ketoacidosis (DKA) in COVID-19 infection. There has been several cases reported on COVID-19 infection precipitating a new diagnosis of type 2 DM (T2DM). However, there is a lack of evidence regarding type 1 DM (T1DM). We report a case of DKA precipitated by COVID-19 in a patient with newly diagnosed T1DM. Recently, case reports and small cross-sectional studies described diabetic patients who develop DKA when infected with COVID-19. The incidence of DKA has been found to be high in patients with T1DM and T2DM admitted to hospital with COVID-19. Case presentation. We present a 29 year-old, previously healthy man with 5 days history of fever, fatigue, vomiting, polydipsia and polyuria. His lab results showed high blood glucose, high anion gap metabolic acidosis and ketonuria diagnostic of DKA. He also tested positive for COVID-19 and his Chest CT was consistent with bilateral COVID 19 pneumonia (ground-glass opacity, consolidation, and crazy-paving pattern). He was successfully managed with intravenous fluids and insulin as per DKA protocol. He required intravenous antibiotics, steroids and oxygenotherapy for COVID-19 pneumonia. He was discharged after 14 days in stable condition. Conclusions. COVID-19 infection can be complicated by DKA and development of DM in previously non-diabetic individuals. It is possible that SARS-CoV-2 may aggravate pancreatic beta cell function and precipitate DKA. Very few cases have been reported in the literature on COVID-19 infection precipitating DKA in a newly diagnosed patient of type 1 diabetes mellitus. Keywords: type 1 diabetes; diabetic ketoacidosis; COVID-19 pneumonia

Introduction

The Coronavirus Disease 19 (COVID-19) is an infectious disease caused by a novel coronavirus, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [1].

During COVID-19 pandemic, diabetes mellitus (DM) was found to be a risk factor for severe disease and worse outcomes [2]. A history of DM was associated with 22.5 % of COVID-19 intensive care unit admissions in one case series [3] and a mortality rate up to 16 % among people with DM and without other comorbidities [4, 5].

The development of diabetic ketoacidosis (DKA) can in itself add to this high mortality in COVID-19 patients. Several studies have demonstrated that COVID-19 can utilize angiotensin-converting enzyme 2 (ACE2) on the surfaces of epithelial cells to bind and gain entry to infected cells [6]. Similar findings were reported during SARS outbreak in 2006 [7]. Binding of ACE2 by SARS-CoV-2 in COVID-19 may play an important role in the pathogenesis of the disease on one hand and could predispose patients to hyperglycemia and development of DM on the other hand. Herein, we describe a patient who was previously healthy, but presented with DKA and new onset of DM complicating COVID-19 pneumonia.

Case presentation

A 29-years old previously healthy man, who was not known to have DM but presented to the emergency department (ED) with fatigue and decrease in activity for 5 days along with generalized body aches and nocturia (about 6–7 times/night). On admission, his temperature was 38.8 °C. He was hemodynamically stable but mildly tachypneic. He did not require supplemental oxygen during the first hours of admission in hospital. He was discharged after 14 days in stable condition.
Given positive contact history, he was tested and confirmed to be infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

He is non-smoker and has no family history of DM.

Upon examination in the emergency room, he was conscious and oriented to time, place and person but looked dehydrated. He was febrile, but he did not display Kussmaul’s breathing. His respiratory rate was fluctuating 22–26/min, and O₂ saturation was 96 % without O₂ therapy. His body mass index was 21.6 kg/m² with no signs of insulin resistance.

Laboratory investigations were significant for hyperglycaemia 479 mg/dl, high anion gap 26 mEq/L, metabolic acidosis: Base excess = −23.2 mEq/L; pH 7.140 and ketonuria +3 (150 mEq/L), confirming the diagnosis of DKA.

The rest of his investigations showed the following:
- BUN: 51 mg/dl, normal range (10–50).
- Creatinine: 1.2 mg/dl, normal range (<1.3).
- SGPT = 20 U/l, normal range (0–46).
- Na: 129 mmol/l, normal range (135–145).
- K: 2.9 mmol/l, normal range (3.5–5.1).
- Cl: 95 mmol/l, normal range (98–107).
- S. lactate: 1.4 mmol/l normal range (0.5–1.1).
- WBC: 11.05 × 10⁹/l, normal range (4–11).
- Lymphocytes: 12.1 %; normal range (25–40 %).
- Hgb: 14.1 gm/l, normal range (12–14).
- Platelets: 281 × 10⁹/l, normal range (140–400).
- Chest X-ray: showed bilateral infiltration.
- Chest CT: CO-RADS category 5; bilateral ground-glass opacities and cavity-paving pattern, 70 % involvement of the lungs, CT severity score = 18/25.
- Insulin 2.74 μIU/l, normal range (2.6–24.9 μIU/l).
- C-peptide 0.856 (ng/ml), normal range (0.8–3.1 ng/ml).
- Anti GAD-IgG — Negative < 5 (< 10 Negative; > 10 Positive).
- HbA1c: 12.8 %.
- Oronasal swab was positive for COVID-19 by real-time reverse transcription-polymerase chain reaction (rRT-PCR) test.

Urinalysis revealed 1000 mg/dl of glucose, 150 mg/dl of ketones and 30 mg/dl of protein.

Inflammatory markers:
- CRP: 25.23 md/ml, normal range (<10 mg/I Negative; >10 mg/I Positive).
- LDH: 792 unit/l, normal range (210–450).
- Ferritin: 1842 mg/dl; normal range (20–400).
- D dimer: 1969 mg/dl, normal range (0–500).
- Cardiac evaluation:
  - ECG normal sinus rhythm.
  - Cardiac enzymes and troponin were normal.

In ED, he received 14 units IV regular insulin as a bolus and 1 litre of IV normal saline and started on DKA protocol with insulin infusion, IV fluids and potassium replacements. Serum electrolytes were closely monitored. DKA resolved after 24 hrs and he was transitioned to subcutaneous insulin therapy. He stayed in the hospital for 14 days and completed ten days course of antibiotics, Levofloxacin 500 mg and Meropenem 3 g. The day after admission he was assisted with oxygen therapy because her saturations fall to 86 %.

He was managed with 20 litres high flow oxygen and 5 days course of dexamethasone 4 mg, two times daily with a gradual decrease of doses. Fourteen days later he was weaned off Oxygen and he was discharged on insulin Aspart 6 UI before each meal and insulin Lantus 14 UI once daily. He was recommended to contact his local endocrinologist after four weeks, for the follow up consult.

Discussion

The patient in this case report was presented with two life threatening conditions, DKA and COVID-19 pneumonia. The prompt recognition and treatment of these conditions is crucial and resulted in good outcome.

DKA is a diabetic emergency and considered to be a common presentation of both T1DM and T2DM. It arise as a result of severe insulin deficiency, increased counter regulatory response which results in the production of ketones [8].

The most common trigger factors are prolonged uncontrolled blood sugar or acute stress including infection (pneumonia, urinary tract infection), acute myocardial infarction or cerebrovascular accident. Also alcohol abuse and drugs like SGLT-2 inhibitors [9] can precipitate a DKA episode.

The patient in this case report was presented with DKA and newly diagnosed T1DM triggered by COVID-19 pneumonia.

The underlying pathophysiology of new onset DM and its severe form DKA in patients with COVID-19 is still not well understood. Viral infection have been widely associated with T1DM pathogenesis.

T1DM is a genetic autoimmune condition where b-cells are destroyed by the auto-reactive CD4⁺ and CD8⁺ T cells causing insulin deficiency [10].

The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), responsible for COVID-19, uses ACE2 receptor to bind and enter to infected cells as a viral complex [6].

Angiotensin converting enzyme (ACE) is the key enzyme in mediating the effects of rennin angiotensin aldosterone system (RAAS) by converting angiotensin I to II. The more recently identified to angiotensin I–VII, was found to be the functional receptor for SARS-CoV-1 and -2 [11].

ACE2 is abundantly present in humans in the epithelia of the lung and small intestine, which might provide possible routes of entry for the SARS-CoV-1 and -2 [12]. Study of 72 human tissues confirmed ACE2 mRNA expression in tissues other than the lung and gastrointestinal system, like testis, cardiovascular, renal, and pancreas [13, 14].

It was found that ACE2 is expressed in the endocrine part of the pancreas. This suggests that SARS coronavirus enters islets cells using ACE2 as its receptor and damages B-cell islets leading to insulin deficiency and development of acute DM [7].

This is supported by the findings of strong immunopositivity for ACE2 in pancreatic islets while exocrine tissues were only weakly positive [15]. Similarly, evidence in diabetic mice demonstrated that ACE2 activity levels were enhanced in the pancreas [15, 16].

In addition to the direct B cell injury, the expression of ACE2 on the surface of the pancreas is downregulated fol-
lowing endocytosis of the virus-ACE2 receptor complex. This in turn can lead to increased concentration of angioten-
sin II and inhibit insulin secretion [17]. These interactions
between SARS-CoV-2 and RAAS might explain the under-
lying mechanism and pathophysiology of DKA.
All these pathophysiological events occurring simulta-
neously with inflammatory stress because of pulmonary
infection might have contributed to the acute worsening of
pancreatic beta cell function and precipitated DKA in this
patient. It remains to be investigated, whether this beta cell da-
mage is transient or permanent.
Our understanding so far is uncertain if this new-onset
diabetes is classic T1DM or some new form of DM.
The presentation of the patient in this case report is con-
sistent with the hypothesis that COVID-19, not only causes
hypercglycaemia and insulin resistance in patients known to
be diabetic [3, 18], but can also predisposes newly diagnosed
diabetes mellitus to DKA which can sometimes be resistant
to treatment [19–21].
The development of diabetes and DKA can further compli-
cate the course of COVID-19 infection. Diabetic patients with
COVID-19 have worse prognosis than nondiabetics [1, 3].
This could be explained in part by high inflammatory and
pro-coagulant state in diabetics including IL-6, C-reactive
protein, serum ferritin, coagulation index, and D-dimer
[2, 4, 22].
While hyperglycemia is seen to increase mortality and
morbidity related to COVID-19, the virus itself can induce/
worser hyperglycaemia, culminating in a vicious cycle [23].

Conclusions
There are enough evidences to conclude that COVID-19
can lead to uncontrolled hyperglycaemia and the develop-
ment of new onset diabetes mellitus which can further com-
PLICATE the course and outcome of COVID-19 infection.
It is possible that SARS-CoV-2 may aggravate pancreatic
beta cell function and precipitate diabetic ketoacidosis
in patients with known or not known diabetes.
Patients with elevated blood sugar and no history of di-
abetes should be evaluated for the possibility of new onset
diabetes mellitus and diabetic ketoacidosis, especially in
the setting of concomitant COVID-19 infection.
Further studies and long term follow-up of children and
adults presenting with new-onset diabetes during this
pandemic is required to fully understand the type of
diabetes induced by COVID-19 and to reveal the exact
underlying pathophysiological mechanism of this serious
condition.

References
1. Peeri NC, Shrestha N, Rahman MS, et al. The SARS,
MERS and novel coronavirus (COVID-19) epidemics, the newest
and biggest global health threats: what lessons have we learned? Int
2. Huang J, Lim MA, Pranata R. Diabetes mellitus is associ-
ated with increased mortality and severity of disease in COVID-19
pneumonia - A systematic review, meta-analysis, and meta-regres-
sion. Diabetes Metab Syndr. 2020 Jul-Aug;14(4):393-403. doi:
Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneu-
4. Guo W, Li M, Dong Y, Zhou H, et al. Diabetes is a risk fac-
tor for the progression and prognosis of COVID-19. Diabetes Metab
5. Goldman N, Fink D, Cai J, Lee YN, Davies Z. High prev-
alence of COVID-19-associated diabetic ketoacidosis in UK sec-
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is
Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr
7. Yang JX, Lin SS, Ji XJ, Guo LM. Binding of SARS corona-
virus to its receptor damages islets and causes acute diabetes. Acta
8. Umpierrez G, Korytkowski M. Diabetic emergencies - ke-
toacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia.
9. Rosenstock J, Ferrannini E. Euglycemic Diabetic Ketoac-
tosis: A Predictable, Detectable, and Preventable Safety Concern
With SGLT2 Inhibitors. Diabetes Care. 2015 Sep;38(9):1638-42.
do: 10.2337/dc15-0353.
10. Filippi CM, von Herrath MG. Viral trigger for type 1 di-
betes: pros and cons. Diabetes. 2008 Nov;57(11):2863-71. doi:
10.2373/dobt07-1023.
verting enzyme 2 is a functional receptor for the SARS coronavirus.
G, van Goor H. Tissue distribution of ACE2 protein, the functional
receptor for SARS coronavirus. A first step in understanding SARS
13. Harmer D, Gilbert M, Borman R, Clark KL. Quantitative
mRNA expression profiling of ACE 2, a novel homologue of angio-
tensin converting enzyme. FEBS Lett. 2002 Dec 4;532(1-2):102-10. doi:
the renin-angiotensin system, and the risk of lower respiratory tract
15. Graus-Fernes F, Souza-Mello V. The renin-angiotensin
system as a target to solve the riddle of endocrine pancreas homeosta-
bipha.2018.10.191.
BO. Endocrine and metabolic link to coronavirus infection. Nat Rev
17. Roca-Ho H, Riera M, Palau V, Pascual J, Sojer ML.
Characterization of ACE and ACE2 Expression within Different Or-
10.3390/ijms18030563.
18. Drucker DJ. Coronavirus Infections and Type 2 Diabe-
tes-Shared Pathways with Therapeutic Implications. Endocr Rev.

Information about authors
Xhardo Elona, MD, PhD, Endocrinologist, Department of Internal Medicine; University Hospital “Shefqet Ndroqi”, Tirana, Albania; e-mail: xhardo.elona@gmail.com; https://orcid.org/0000-0002-6811-5520
Kapisyzi Perlat, MD, Pulmonologist, Division of pulmonary diseases; Faculty of Medicine; University Hospital “Shefqet Ndroqi”, Tirana, Albania; https://orcid.org/0000-0002-7296-404X
Rada A., MD, Pulmonologist, Division of pulmonary diseases; Faculty of Medicine; University Hospital “Shefqet Ndroqi”, Tirana, Albania

Conflicts of interests. Authors declare the absence of any conflicts of interests and their own financial interest that might be construed to influence the results or interpretation of their manuscript.

Dіабетичний кетоацидоз, спричинений COVID-19, у пацієнта з уперше діагностованим цукровим діабетом


Ключові слова: цукровий діабет 1-го типу; діабетичний кетоацидоз; пневмонія; COVID-19

Received 18.06.2021
Revised 14.07.2021
Accepted 02.08.2021

Vol. 17, No. 5, 2021
http://iej.zaslavsky.com.ua

425